Cipla receives WHO pre-qualification for the anti-malaria drug
The anti-malarial drug from Cipla receives pre-qualification from WHO.
New Delhi, October 3, 2012: Drug firm Cipla said that the anti-malarial drug developed by the Drugs for Neglected Diseases initiative (DNDi) has received pre-qualification from the World Health Organisation (WHO).
It is worth noting here that the drug firm is manufacturing the fixed dose combination drug of Artesunate and Mefloquine (ASMQ FDC) under a technology transfer agreement with DNDi.
“This Cipla-manufactured ASMQ FDC is the first artesunate-mefloquine FDC to be prequalified by WHO and is recommended for the treatment of malaria,” Cipla said in a statement.
"The prequalification announcement is recognition that ASMQ FDC meets WHO's high quality standards and we aim to make this treatment widely available throughout Asia," said Jaideep Gogtay, Medical Director, Cipla.
It may be noted here that pre-qualification is a process under which drug companies need to meet the certain conditions stipulated by the WHO’s high quality standards in order to be eligible to supply vaccines to UN procurement agencies globally.
ASMQ FDC was originally developed by DNDi and the Brazilian government-owned pharmaceutical company Farmanguinhos/Fiocruz and was registered in Brazil in 2008. In fact, a technology transfer agreement between Farmanguinhos and Cipla was signed in 2010 with a view to facilitate the implementations of ASMQ FDC in Asia.